Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase II NCT07032662

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting • Phase II • NCT07032662.

📅 10 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT07032662
Start
2025-03-18
Completion
2028-08
ClinicaliQ Trial Snapshot
  • Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting • Phase II • NCT07032662.
  • A study testing whether a new drug called Imeroprubart helps adults with chronic nerve inflammation and weakness.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP. Conditions: Chronic Inflammatory Demyelinating Polyneuropathy Interventions: Imeroprubart, Placebo Lead Sponsor: Immunovant Sciences GmbH Planned Enrollment: 162 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn